FEATURED COMPANIES
- Amgen Inc.
- Celltrion Inc.
- F. Hoffmann-La Roche Ltd.
- Novartis AG
- Pfizer Inc.
1h Free Analyst Time
Speak directly to the analyst to clarify any post sales queries you may have.
Global Anti-CD20 Monoclonal Antibodies (mABs) Market: About this market
The anti-CD20 monoclonal antibodies (mABs) market analysis considers sales from oncology, neurology, and immunology. The analysis also considers the sales of anti-CD20 monoclonal antibodies (mABs) in Asia, Europe, North America, and ROW. In 2018, the oncology segment had a significant market share, and this trend is expected to continue over the forecast period. Factors such as growing awareness of cancer treatment through anti-CD20 mABs will help the oncology segment to maintain its market position. Also, the global anti-CD20 monoclonal antibodies (mABs) market report looks at factors such as increased use of combination therapies, high target affinity, and specificity of anti-CD20 mABs, and strong pipeline and recent approvals. However, adverse effects of anti-CD20 mABs, the introduction of rituximab biosimilars, and the emergence of alternative therapies may hamper the growth of the anti-CD20 monoclonal antibodies (mABs) industry over the forecast period.
Global Anti-CD20 Monoclonal Antibodies (mABs) Market: Overview
High target affinity and specificity of anti-CD20 mABs
Anti-CD20 mABs are proven highly effective as target therapies in treating CD20-related indications. These antibodies attack CD20 antigen on cancer cells, unlike conventional therapies. The growing R&D in this space and positive results of clinical trials for late-stage molecules will support the growth prospects of the global anti-CD20 monoclonal antibodies (mABs) market, leading it at a CAGR of over 9% during the forecast period.
Development of CD20 bispecific antibodies
The bispecific antibodies are a combination of two or more antigens into a single product and can bind two or more specific targets, more than one pathway at the target disease. The blocking of the several biological pathways allows bispecific antibodies to display a synergistic effect, which is unachievable with a mixture of monospecific antibodies. This helps in optimizing expenses by reducing the cost of drug development and clinical trials. This development is expected to have a positive impact on the overall market growth.
Competitive Landscape
With the presence of several major players, the global anti-CD20 monoclonal antibodies (mABs) market is fragmented. The robust vendor analysis is designed to help clients improve their market position, and in line with this, this report provides a detailed analysis of several leading anti-CD20 monoclonal antibodies (mABs) manufacturers, that include Amgen Inc., Celltrion Inc., F. Hoffmann-La Roche Ltd., Novartis AG, Pfizer Inc.
Also, the anti-CD20 monoclonal antibodies (mABs) market analysis report includes information on upcoming trends and challenges that will influence market growth. This is to help companies strategize and leverage on all forthcoming growth opportunities.
The anti-CD20 monoclonal antibodies (mABs) market analysis considers sales from oncology, neurology, and immunology. The analysis also considers the sales of anti-CD20 monoclonal antibodies (mABs) in Asia, Europe, North America, and ROW. In 2018, the oncology segment had a significant market share, and this trend is expected to continue over the forecast period. Factors such as growing awareness of cancer treatment through anti-CD20 mABs will help the oncology segment to maintain its market position. Also, the global anti-CD20 monoclonal antibodies (mABs) market report looks at factors such as increased use of combination therapies, high target affinity, and specificity of anti-CD20 mABs, and strong pipeline and recent approvals. However, adverse effects of anti-CD20 mABs, the introduction of rituximab biosimilars, and the emergence of alternative therapies may hamper the growth of the anti-CD20 monoclonal antibodies (mABs) industry over the forecast period.
Global Anti-CD20 Monoclonal Antibodies (mABs) Market: Overview
High target affinity and specificity of anti-CD20 mABs
Anti-CD20 mABs are proven highly effective as target therapies in treating CD20-related indications. These antibodies attack CD20 antigen on cancer cells, unlike conventional therapies. The growing R&D in this space and positive results of clinical trials for late-stage molecules will support the growth prospects of the global anti-CD20 monoclonal antibodies (mABs) market, leading it at a CAGR of over 9% during the forecast period.
Development of CD20 bispecific antibodies
The bispecific antibodies are a combination of two or more antigens into a single product and can bind two or more specific targets, more than one pathway at the target disease. The blocking of the several biological pathways allows bispecific antibodies to display a synergistic effect, which is unachievable with a mixture of monospecific antibodies. This helps in optimizing expenses by reducing the cost of drug development and clinical trials. This development is expected to have a positive impact on the overall market growth.
Competitive Landscape
With the presence of several major players, the global anti-CD20 monoclonal antibodies (mABs) market is fragmented. The robust vendor analysis is designed to help clients improve their market position, and in line with this, this report provides a detailed analysis of several leading anti-CD20 monoclonal antibodies (mABs) manufacturers, that include Amgen Inc., Celltrion Inc., F. Hoffmann-La Roche Ltd., Novartis AG, Pfizer Inc.
Also, the anti-CD20 monoclonal antibodies (mABs) market analysis report includes information on upcoming trends and challenges that will influence market growth. This is to help companies strategize and leverage on all forthcoming growth opportunities.
Note: Product cover images may vary from those shown
FEATURED COMPANIES
- Amgen Inc.
- Celltrion Inc.
- F. Hoffmann-La Roche Ltd.
- Novartis AG
- Pfizer Inc.
PART 01: EXECUTIVE SUMMARY
PART 02: SCOPE OF THE REPORT
PART 08: GEOGRAPHIC LANDSCAPE
PART 10: DRIVERS AND CHALLENGES
Exhibit 01: Product overview
Exhibit 02: Global pharmaceuticals market
Exhibit 03: Segments of global pharmaceuticals market
Exhibit 04: Market characteristics
Exhibit 05: Market segments
Exhibit 06: Market definition - Inclusions and exclusions checklist
Exhibit 07: Market size 2018
Exhibit 08: Global market: Size and forecast 2018-2023 ($ millions)
Exhibit 09: Global market: Year-over-year growth 2019-2023 (%)
Exhibit 10: Five forces analysis 2018
Exhibit 11: Five forces analysis 2023
Exhibit 12: Bargaining power of buyers
Exhibit 13: Bargaining power of suppliers
Exhibit 14: Threat of new entrants
Exhibit 15: Threat of substitutes
Exhibit 16: Threat of rivalry
Exhibit 17: Market condition - Five forces 2018
Exhibit 18: Product - Market share 2018-2023 (%)
Exhibit 19: Comparison by product
Exhibit 20: Oncology - Market size and forecast 2018-2023 ($ millions)
Exhibit 21: Approved mABs for cancer indications
Exhibit 22: Oncology - Year-over-year growth 2019-2023 (%)
Exhibit 23: Neurology - Market size and forecast 2018-2023 ($ millions)
Exhibit 24: Neurology - Year-over-year growth 2019-2023 (%)
Exhibit 25: Immunology - Market size and forecast 2018-2023 ($ millions)
Exhibit 26: Immunology - Year-over-year growth 2019-2023 (%)
Exhibit 27: Market opportunity by product
Exhibit 28: Customer landscape
Exhibit 29: Market share by geography 2018-2023 (%)
Exhibit 30: Geographic comparison
Exhibit 31: North America - Market size and forecast 2018-2023 ($ millions)
Exhibit 32: Some of the approved anti-CD20 mABs in US
Exhibit 33: North America - Year-over-year growth 2019-2023 (%)
Exhibit 34: Top 3 countries in North America
Exhibit 35: Europe - Market size and forecast 2018-2023 ($ millions)
Exhibit 36: Some of the approved anti-CD20 mABs in Europe
Exhibit 37: Europe - Year-over-year growth 2019-2023 (%)
Exhibit 38: Top 3 countries in Europe
Exhibit 39: Asia - Market size and forecast 2018-2023 ($ millions)
Exhibit 40: Asia - Year-over-year growth 2019-2023 (%)
Exhibit 41: Top 3 countries in Asia
Exhibit 42: ROW - Market size and forecast 2018-2023 ($ millions)
Exhibit 43: ROW - Year-over-year growth 2019-2023 (%)
Exhibit 44: Top 3 countries in ROW
Exhibit 45: Key leading countries
Exhibit 46: Market opportunity
Exhibit 47: Some of the major combination therapies for anti-CD20 mABs
Exhibit 48: Serious side effects of anti-CD20 mABs
Exhibit 49: Effect on RITUXAN sales after the launch of biosimilars
Exhibit 50: Some of the recently approved rituximab biosimilars
Exhibit 51: Impact of drivers and challenges
Exhibit 52: Some of the CD20 bispecific antibodies under development
Exhibit 53: Vendor landscape
Exhibit 54: Landscape disruption
Exhibit 55: Vendors covered
Exhibit 56: Vendor classification
Exhibit 57: Market positioning of vendors
Exhibit 58: Amgen Inc. - Vendor overview
Exhibit 59: Amgen Inc. - Organizational developments
Exhibit 60: Amgen Inc. - Geographic focus
Exhibit 61: Amgen Inc. - Key offerings
Exhibit 62: Amgen Inc. - Key customers
Exhibit 63: Celltrion Inc. - Vendor overview
Exhibit 64: Celltrion Inc. - Product segments
Exhibit 65: Celltrion Inc. - Organizational developments
Exhibit 66: Celltrion Inc. - Geographic focus
Exhibit 67: Celltrion Inc. - Segment focus
Exhibit 68: Celltrion Inc. - Key offerings
Exhibit 69: Celltrion Inc. - Key customers
Exhibit 70: F. Hoffmann-La Roche Ltd. - Vendor overview
Exhibit 71: F. Hoffmann-La Roche Ltd. - Business segments
Exhibit 72: F. Hoffmann-La Roche Ltd. - Organizational developments
Exhibit 73: F. Hoffmann-La Roche Ltd. - Geographic focus
Exhibit 74: F. Hoffmann-La Roche Ltd. - Segment focus
Exhibit 75: F. Hoffmann-La Roche Ltd. - Key offerings
Exhibit 76: F. Hoffmann-La Roche Ltd. - Key customers
Exhibit 77: Novartis AG - Vendor overview
Exhibit 78: Novartis AG - Business segments
Exhibit 79: Novartis AG - Organizational developments
Exhibit 80: Novartis AG - Geographic focus
Exhibit 81: Novartis AG - Segment focus
Exhibit 82: Novartis AG - Key offerings
Exhibit 83: Novartis AG - Key customers
Exhibit 84: Pfizer Inc. - Vendor overview
Exhibit 85: Pfizer Inc. - Business segments
Exhibit 86: Pfizer Inc. - Organizational developments
Exhibit 87: Pfizer Inc. - Geographic focus
Exhibit 88: Pfizer Inc. - Segment focus
Exhibit 89: Pfizer Inc. - Key offerings
Exhibit 90: Pfizer Inc. - Key customers
Exhibit 91: Validation techniques employed for market sizing
Exhibit 92: Definition of market positioning of vendors
PART 02: SCOPE OF THE REPORT
- Preface
- Currency conversion rates for US$
- Market ecosystem
- Market characteristics
- Market segmentation analysis
- Market definition
- Market sizing 2018
- Market size and forecast 2018-2023
- Bargaining power of buyers
- Bargaining power of suppliers
- Threat of new entrants
- Threat of substitutes
- Threat of rivalry
- Market condition
- Market segmentation by product
- Comparison by product
- Oncology - Market size and forecast 2018-2023
- Neurology - Market size and forecast 2018-2023
- Immunology - Market size and forecast 2018-2023
- Market opportunity by product
PART 08: GEOGRAPHIC LANDSCAPE
- Geographic segmentation
- Geographic comparison
- North America - Market size and forecast 2018-2023
- Europe - Market size and forecast 2018-2023
- Asia - Market size and forecast 2018-2023
- ROW - Market size and forecast 2018-2023
- Key leading countries
- Market opportunity
PART 10: DRIVERS AND CHALLENGES
- Market drivers
- Market challenges
- Increasing awareness about therapeutic areas
- Presence of reimbursement and patient assistance programs
- Development of CD20 bispecific antibodies
- Overview
- Landscape disruption
- Vendors covered
- Vendor classification
- Market positioning of vendors
- Amgen Inc.
- Celltrion Inc.
- F. Hoffmann-La Roche Ltd.
- Novartis AG
- Pfizer Inc.
- Research methodology
- List of abbreviations
- Definition of market positioning of vendors
Exhibit 01: Product overview
Exhibit 02: Global pharmaceuticals market
Exhibit 03: Segments of global pharmaceuticals market
Exhibit 04: Market characteristics
Exhibit 05: Market segments
Exhibit 06: Market definition - Inclusions and exclusions checklist
Exhibit 07: Market size 2018
Exhibit 08: Global market: Size and forecast 2018-2023 ($ millions)
Exhibit 09: Global market: Year-over-year growth 2019-2023 (%)
Exhibit 10: Five forces analysis 2018
Exhibit 11: Five forces analysis 2023
Exhibit 12: Bargaining power of buyers
Exhibit 13: Bargaining power of suppliers
Exhibit 14: Threat of new entrants
Exhibit 15: Threat of substitutes
Exhibit 16: Threat of rivalry
Exhibit 17: Market condition - Five forces 2018
Exhibit 18: Product - Market share 2018-2023 (%)
Exhibit 19: Comparison by product
Exhibit 20: Oncology - Market size and forecast 2018-2023 ($ millions)
Exhibit 21: Approved mABs for cancer indications
Exhibit 22: Oncology - Year-over-year growth 2019-2023 (%)
Exhibit 23: Neurology - Market size and forecast 2018-2023 ($ millions)
Exhibit 24: Neurology - Year-over-year growth 2019-2023 (%)
Exhibit 25: Immunology - Market size and forecast 2018-2023 ($ millions)
Exhibit 26: Immunology - Year-over-year growth 2019-2023 (%)
Exhibit 27: Market opportunity by product
Exhibit 28: Customer landscape
Exhibit 29: Market share by geography 2018-2023 (%)
Exhibit 30: Geographic comparison
Exhibit 31: North America - Market size and forecast 2018-2023 ($ millions)
Exhibit 32: Some of the approved anti-CD20 mABs in US
Exhibit 33: North America - Year-over-year growth 2019-2023 (%)
Exhibit 34: Top 3 countries in North America
Exhibit 35: Europe - Market size and forecast 2018-2023 ($ millions)
Exhibit 36: Some of the approved anti-CD20 mABs in Europe
Exhibit 37: Europe - Year-over-year growth 2019-2023 (%)
Exhibit 38: Top 3 countries in Europe
Exhibit 39: Asia - Market size and forecast 2018-2023 ($ millions)
Exhibit 40: Asia - Year-over-year growth 2019-2023 (%)
Exhibit 41: Top 3 countries in Asia
Exhibit 42: ROW - Market size and forecast 2018-2023 ($ millions)
Exhibit 43: ROW - Year-over-year growth 2019-2023 (%)
Exhibit 44: Top 3 countries in ROW
Exhibit 45: Key leading countries
Exhibit 46: Market opportunity
Exhibit 47: Some of the major combination therapies for anti-CD20 mABs
Exhibit 48: Serious side effects of anti-CD20 mABs
Exhibit 49: Effect on RITUXAN sales after the launch of biosimilars
Exhibit 50: Some of the recently approved rituximab biosimilars
Exhibit 51: Impact of drivers and challenges
Exhibit 52: Some of the CD20 bispecific antibodies under development
Exhibit 53: Vendor landscape
Exhibit 54: Landscape disruption
Exhibit 55: Vendors covered
Exhibit 56: Vendor classification
Exhibit 57: Market positioning of vendors
Exhibit 58: Amgen Inc. - Vendor overview
Exhibit 59: Amgen Inc. - Organizational developments
Exhibit 60: Amgen Inc. - Geographic focus
Exhibit 61: Amgen Inc. - Key offerings
Exhibit 62: Amgen Inc. - Key customers
Exhibit 63: Celltrion Inc. - Vendor overview
Exhibit 64: Celltrion Inc. - Product segments
Exhibit 65: Celltrion Inc. - Organizational developments
Exhibit 66: Celltrion Inc. - Geographic focus
Exhibit 67: Celltrion Inc. - Segment focus
Exhibit 68: Celltrion Inc. - Key offerings
Exhibit 69: Celltrion Inc. - Key customers
Exhibit 70: F. Hoffmann-La Roche Ltd. - Vendor overview
Exhibit 71: F. Hoffmann-La Roche Ltd. - Business segments
Exhibit 72: F. Hoffmann-La Roche Ltd. - Organizational developments
Exhibit 73: F. Hoffmann-La Roche Ltd. - Geographic focus
Exhibit 74: F. Hoffmann-La Roche Ltd. - Segment focus
Exhibit 75: F. Hoffmann-La Roche Ltd. - Key offerings
Exhibit 76: F. Hoffmann-La Roche Ltd. - Key customers
Exhibit 77: Novartis AG - Vendor overview
Exhibit 78: Novartis AG - Business segments
Exhibit 79: Novartis AG - Organizational developments
Exhibit 80: Novartis AG - Geographic focus
Exhibit 81: Novartis AG - Segment focus
Exhibit 82: Novartis AG - Key offerings
Exhibit 83: Novartis AG - Key customers
Exhibit 84: Pfizer Inc. - Vendor overview
Exhibit 85: Pfizer Inc. - Business segments
Exhibit 86: Pfizer Inc. - Organizational developments
Exhibit 87: Pfizer Inc. - Geographic focus
Exhibit 88: Pfizer Inc. - Segment focus
Exhibit 89: Pfizer Inc. - Key offerings
Exhibit 90: Pfizer Inc. - Key customers
Exhibit 91: Validation techniques employed for market sizing
Exhibit 92: Definition of market positioning of vendors
Note: Product cover images may vary from those shown
FEATURED COMPANIES
- Amgen Inc.
- Celltrion Inc.
- F. Hoffmann-La Roche Ltd.
- Novartis AG
- Pfizer Inc.
The following companies are recognised as the key players in the global anti-CD20 monoclonal antibodies (mABs) market: Amgen Inc., Celltrion Inc., F. Hoffmann-La Roche Ltd., Novartis AG, Pfizer Inc.
Commenting on the report, an analyst from the research team said: “The latest trend gaining momentum in the market is the development of CD20 bispecific antibodies.”
According to the report, one of the major drivers for this market is high target affinity and specificity of anti-CD20 mABs.
Further, the report states that one of the major factors hindering the growth of this market is the adverse effects of anti-CD20 mABs
The study was conducted using an objective combination of primary and secondary information, including inputs from key participants in the industry. The report contains a comprehensive market and vendor landscape in addition to a SWOT analysis of the key vendors.
Commenting on the report, an analyst from the research team said: “The latest trend gaining momentum in the market is the development of CD20 bispecific antibodies.”
According to the report, one of the major drivers for this market is high target affinity and specificity of anti-CD20 mABs.
Further, the report states that one of the major factors hindering the growth of this market is the adverse effects of anti-CD20 mABs
The study was conducted using an objective combination of primary and secondary information, including inputs from key participants in the industry. The report contains a comprehensive market and vendor landscape in addition to a SWOT analysis of the key vendors.
Note: Product cover images may vary from those shown
- Amgen Inc.
- Celltrion Inc.
- F. Hoffmann-La Roche Ltd.
- Novartis AG
- Pfizer Inc.
Note: Product cover images may vary from those shown
LOADING...
